TYK2-Selective Compound Scaffolds for Lower JAK Off-Target Effects

The patent applies local quality by designing JAK inhibitors with specific molecular structures (Formula I compounds) that possess selective binding characteristics for TYK2 over other JAK family members. The compounds incorporate specific substituents (R1-R6 groups) and structural motifs that create preferential interaction with TYK2's ATP binding site, thereby achieving localized therapeutic effect on TYK2-mediated pathways while minimizing off-target effects on JAK1, JAK2, and JAK3.

The patent employs parameter changes by systematically varying molecular parameters of the JAK inhibitor compounds, including substituent types (hydrophobic, polar, aromatic groups), binding affinity constants, and selectivity ratios. The compounds are designed with specific Ki values against TYK2 and other JAK members, creating a gradient of selectivity that optimizes therapeutic index while maintaining broad disease coverage through TYK2-specific mechanism.

The patent applies universality by designing a master structural scaffold (Formula I core structure) that can be modified to target multiple disease states through TYK2 inhibition. The compounds cover a broad range of indications including psoriasis, inflammatory bowel disease, rheumatoid arthritis, and other TYK2-mediated conditions, reducing development complexity by using a single platform approach rather than developing separate inhibitors for each disease.

The patent employs segmentation by dividing the molecular structure into distinct functional segments: the core JAK inhibitor scaffold (R1-R6 substituents), the TYK2-specific binding pharmacophore, and the pharmacokinetic optimization moieties. This modular design allows independent optimization of each segment for specific disease indications while maintaining overall TYK2 selectivity, thereby managing development complexity through systematic modular assembly.